News

In the long history of diabetes treatment, both Sanofi and Takeda have brought to market numerous therapeutic drugs to treat diabetes over the years and have built up

PH-COPD is a serious complication of COPD that can affect the health status of patients with this condition. Current standard of care for PH-COPD patients is primarily limited

FDA breakthrough therapy status helps in accelerating the development and review of drugs for serious or life-threatening conditions if preliminary clinical evidence indicates the therapy may show a

The Phase IIb trial, called AURA–LV (Aurinia Urine protein Reduction in Active Lupus with voclosporin) or AURA, is planned to be carried out in about 20 countries. The

The agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics. As part of the deal, Liomont will provide Oncobiologics with upfront licensing and

These two patents broadly cover methods and uses for AC-201 as monotherapy or in combination with other lipid lower agents to treat patients with type II diabetes and

Following the launch of Herceptin SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche’s oncology products using Halozyme’s patented EnhanzeTM (recombinant

The company’s Vice President of Sales Callum Baylis-Duffield said of the exemption, "As we gear up to commence marketing Phytofare in the coming quarter, qualifying for this exemption

The patent claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer. Prostate cancer typically